Dr. Yongjin Park named Canada Research Chair
We are pleased to announce that Dr. Yongjin Park has been named Canada Research Chair in Integrative Causality Inference of Cancer Mechanisms (Tier 2).
We are pleased to announce that Dr. Yongjin Park has been named Canada Research Chair in Integrative Causality Inference of Cancer Mechanisms (Tier 2).
A recent study published in the Journal of Clinical Investigation found that certain cancer-causing proteins can switch on parts of a person’s genetic material that were previously inactive, potentially contributing to the development and progression of Ewing sarcoma and prostate cancer. This finding helps researchers understand why the environment around a tumour may cause inflammation and suppress the immune system, which can make it challenging to successfully treat solid tumours with immunotherapy.
Congratulations to BC Cancer researchers who were awarded federal grants through the 2023 Canada Foundation for Innovation (CFI).
Internationally recognized breast cancer researcher Dr. Samuel Aparicio (Aparicio Lab) has been named the 2022 recipient of the Canadian Cancer Society’s Robert L. Noble Prize.
Congratulations to Dr. Poul Sorensen, a UBC Professor of Pathology and a Distinguished Scientist at BC Cancer, for being appointed as an International Ambassador to the Technical University of Munich (TUM), in Germany. These prestigious Ambassadorships are given by TUM to renowned international researchers that have formally conducted research at TUM, and who have retained particularly close ties to the university.
Congratulations to Drs. Poul Sorensen and Gregg Morin, at BC Cancer, and Dr. Wei Li, at the University of Pittsburgh, for being awarded $500,000 USD from the Osteosarcoma Institute for their project titled “Harnessing the osteosarcoma surfaceome for immunotherapy targets to block metastatic capacity”
Dr. Poul Sorensen, Distinguished Scientist at BC Cancer, in collaboration with Dr. Kevin Hay, Clinician-Ccientist at BC Cancer, and Dr. Wei Li, Assistant Professor at the University of Pittsburgh, received support from the Rutledge Cancer Foundation to develop and optimize novel immunotherapies targeting the surface protein IL1RAP for the treatment of Ewing sarcoma.
Canadian research teams, including several from BC Cancer, will receive a total of $2.4 million to advance cancer research and treatment following new awards in the 2023 Terry Fox New Frontiers Program Project Grant (PPG) competition.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.